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A B S T R A C T
The use of NSAIDs (non-steroidal anti-inflammatory drugs), although of great therapeutic value
clinically, is limited by their tendency to cause mucosal damage in the gastrointestinal tract. In the
small intestine, the effects these drugs have been shown to produce include inhibition of cyclo-
oxygenase, mitochondrial dysfunction and free radical-induced oxidative changes, all of which
contribute to the mucosal damage seen. Glutamine is a fuel preferentially used by enterocytes
and is known to contribute to maintaining the integrity of these cells. In the present study,
we investigated the effect of glutamine on indomethacin-induced changes in the small intestinal
mucosa. Rats were given 2 % glutamine or glutamic acid or isonitrogenous amino acids, glycine or
alanine, in the diet for 7 days. Indomethacin was then administered orally at a dose of 40 mg/kg
of body weight. After 1 h, the small intestine was removed and used for the measurement of
parameters of oxidative stress and mitochondrial and BBM (brush border membrane) function.
Evidence of oxidative stress was found in the mucosa of the small intestine of drug-treated rats, as
indicated by significantly increased activity of xanthine oxidase (P< 0.001) and myeloperoxidase
(P< 0.001), with corresponding decreases in the levels of several free radical scavenging enzymes
and α-tocopherol (P< 0.001 in all cases). Levels of products of peroxidation were also significantly
elevated (P< 0.001 for all the parameters measured). In addition, oxidative stress was evident in
isolated intestinal mitochondria and BBMs (P< 0.001 for all the parameters measured), with
associated alterations in function of these organelles (P< 0.001 for all the parameters measured).
Supplementation of the diet with glutamine or glutamic acid prior to treatment with indomethacin
produced significant amelioration in all the effects produced by the drug in the small intestine
(P< 0.001 for all the parameters measured). Glycine and alanine were found to be much less
effective in these respects.
INTRODUCTION
NSAIDs (non-steroidal anti-inflammatory drugs) are
used extensively in clinical medicine as analgesics,
antipyretics and anti-inflammatory agents. They are
known to exert their therapeutic effects through
inhibition of COX (cyclo-oxygenase) [1], a key enzyme
in the formation of prostaglandins. In spite of their
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therapeutic utility, however, these drugs show a tendency
to causemucosal damage in the gastrointestinal tract [2], a
circumstance that limits their use. The resultant decrease
in cellular levels of prostaglandins, associated with the
use of these drugs, is also widely held to be the basis
of the gastric toxicity caused by them. This does not,
however, fully explain the mechanism of damage in the
small intestine [3]. One of the hypotheses advanced to
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explain the pathogenesis ofNSAID-induced enteropathy
involves the action of the drug in uncoupling or inhibiting
oxidative phosphorylation. Indomethacin, a commonly
used NSAID, has been shown to have these effects
in isolated liver mitochondrial preparations [4]. This
finding has been corroborated by studies that have shown
decreases in the energy charge in jejunal tissue in vitro in
the presence of the drug [5].
Other factors have also been shown to be involved
in the pathogenesis of NSAID-induced damage in the
intestine.Oxidative stress is one such putativemechanism
[6]. Earlier work on the effects of indomethacin on the
small intestine has shown that the drug produces free
radical-induced damage and mitochondrial dysfunction
in the enterocytes, with the villus tip cells being parti-
cularly susceptible to such effects [7]. Oxidative stress
has also been reported in the intestinal BBMs (brush
border membranes), leading to structural and functional
impairment in these membranes [8].
Glutamine is one of the most abundant free amino
acids in the body. It acts as a major metabolic fuel for
rapidly dividing cells, such as intestinal epithelial cells and
cells of the immune system. It plays a role in protecting
against mucosal atrophy seen in prolonged states of
parenteral nutrition, in the healing of gastrointestinal
mucosa after damage due to either radio- or chemo-
therapy, improving gut and systemic immune function
and reducing episodes of bacterial translocation [9,10].
It is also known to play a role in signal transduction
and cellular responses involving stress and anti-apoptotic
genes [11]. In addition, glutamine has been shown to
attenuate the leucocyte adhesion and increase in intestinal
permeability caused by NSAIDs [12,13]. In the present
study, we investigated the effects of oral glutamine
supplementation on indomethacin-induced changes in
the small intestine.
MATERIALS AND METHODS
Materials
Indomethacin, arsenazo-III, Hepes, Trypan Blue,
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide], DMSO, ADP, succinate, Tris/HCl,
CDNB (1-chloro-2,4-dinitrobenzene), DPNH (2,4-
dinitrophenylhydrazine), O-dianisidine dihydrochlor-
ide, EDTA,BSA,DTNB [5,5′-dithio-bis-(2-nitrobenzoic
acid], NAD, NADPH, GSSG (oxidized glutathione),
GSH (reduced glutathione), TBA (2-thiobarbituric
acid) and xanthine were obtained from Sigma. PEG
(polyethylene glycol) 4000 was obtained from Fluka.
[14C]Glucose was obtained from Bhabha Atomic
Research Center (Bombay, India). All other chemicals
usedwere of analytical grade.Milliporemembranes (pore
size, 0.45 µm) were obtained from Millipore, India.
Animals
Male albino rats (200–250 g), exposed to 12 h light/dark
cycles and fed with water and rat chow ad libitum, were
used for the experiments. All the procedures performed
on the animals had been approved by the Committee for
the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA), Government of India.
Protocol for administration of
experimental compounds
Male rats were fasted overnight and treated with
indomethacin (40 mg/kg of body weight) by gavage
[7,8]. Control animals received an equal volume of the
vehicle for the drug (5% sodium bicarbonate). After
1 h, the animals were killed by cervical dislocation, their
abdomenswere opened immediately and the entire length
of the small intestine was removed.
For studies on the effect of pretreatment with various
amino acids, the following protocols were followed. Rats
were placed on powdered rat chow supplemented with
2% (w/w) glutamine for 7 days. The same concentrations
of glutamic acid and isonitrogenous amino acids, glycine
or alanine, were also administered for the same duration
for the purpose of comparison. On day 8, the rats were
treated with indomethacin and, 1 h later, the animals
were killed. Each experimental group used consisted of
six individual animals.
Isolation of enterocytes
Total enterocytes were isolated from the small in-
testine by the metal chelation method [14]. Briefly,
the intestine was washed with KH (Krebs–Henseleit)
buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl,
1.18 mM KH2PO4 and 1.9 mM MgSO4, pH 7.4), filled
with the same buffer containing 5 mMEDTA and 0.25%
(w/v) albumin and incubated at 37 ◦C for 12 min in a
beaker containing KH buffer alone. After incubation, the
intestine was washed with ice-cold KH buffer containing
0.25% (w/v) albumin and then filled with the same
buffer. Enterocytes were detached by gently rubbing
the intestine along its entire length. Following this, the
intestinal fluid containing detached cells was centrifuged
at 900 g for 5 min. The cells in the pellet obtained were
washed twice and the final preparation of enterocytes was
suspended in 25 mM PBS (pH 7.4).
Assessment of cellular respiration
Cell viability of the isolated enterocytes was assessed by
dye-exclusionmethod using TrypanBlue [15]. An aliquot
of the cell suspension was mixed with 0.1% Trypan Blue
in PBS. A portion (10 µl) of this mixture was placed in
a Neubar chamber. Both the total and viable number of
cells were counted and the percentage of viable cells was
calculated. The degree of MTT reduction by the cells
was measured as described previously [16].
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Isolation of mitochondria
Mitochondria were isolated from the enterocytes by
differential centrifugation as described previously [17].
The purity of the preparationwas checked by enrichment
of the marker enzyme succinate dehydrogenase [18].
Preparation of mucosal homogenate
and assay of enzymes
The small intestinewas opened up along its length and the
mucosa scraped using a glass slide. This material was
used for the preparation of 3% homogenates using Tris/
mannitol buffer [2 mM Tris/HCl (pH 7.1) containing
50 mM mannitol] as described previously [19].
MPO (myeloperoxidase) activity was measured as
describedpreviously [20],with certainmodifications. The
homogenate was first treated with hexadecyltrimethyl
ammonium bromide to a final concentration of 0.5%
of the compound and centrifuged at 1000 g for 4 min.
The supernatant obtained was used for the measurement
of MPO activity. The assay system consisted of 50 mM
potassium phosphate buffer, pH 6, 0.167 mg of o-
dianisidine, 0.1 µMH2O2 and an aliquot of the enzyme.
The rate of decomposition of H2O2 by MPO with o-
dianisidine as the hydrogen donor was determined by
measuring the rate of colour development at 460 nm.
Activities of XO (xanthine oxidase) [21], XDH
(xanthine dehydrogenase) [21], catalase [22], glutathione
peroxidase [23], glutathione reductase [24] and SOD
(superoxide dismutase) [25] were measured in the
homogenate as described previously.
Isolation of BBM vesicles
BBM vesicles were prepared from the mucosal scrapings
[19]. Purity of the preparation was checked by enrich-
ment of the marker enzyme alkaline phosphatase [26].
Assessment of mitochondrial function
Various parameters of mitochondrial function were
assessed in the isolated organelles. Oxygen uptake
was determined polarographically using a Clark type
electrode (YSI Model 5300 Biological Oxygen Monitor)
[27]. MTT reduction was determined using a microtitre
plate as described previously [16]. The amount of
MTT formazan formed was calculated using the
molar absorption coefficient of MTT formazan ε570 of
17 000 M−1 cm−1 at pH 7.4–8.0. Permeability of the inner
mitochondrial membrane was determined by measuring
the decrease in absorbance at 540 nm [16]. Calcium
uptake by the mitochondria was followed by measuring
the changes in absorption spectrum of arsenazo-III [28].
Assessment of parameters of
oxidative stress
Homogenates were used for measurements of various
parameters of oxidative stress. MDA (malondialdehyde)
contentwasmeasured as described previouslywithminor
modifications [29]. The mixture consisted of 0.8 ml of
sample (corresponding to approx. 1 mg of protein),
0.2 ml of 8.1% (w/v) SDS, 1.5 ml of 20% acetic acid
and 1.5 ml of 0.8% TBA (2-thiobarbituric acid). The
mixture was heated in a boiling water bath for
60 min. The absorbance of the supernatant was read at
532 nm. The amount of lipid peroxides present that
reacted with TBA was calculated from a standard curve
prepared using 1,1′,3,3′ tetramethoxypropane.
Other parameters measured in the homogenate were
conjugated dienes [30], protein carbonyl [31], thiols
[32] and α-tocopherol [33]. These parameters were
also measured in mitochondrial and BBM suspensions.
Protein was estimated by Lowry’s method [34], using
BSA as standard.
Measurement of D-glucose uptake
Isolated BBMs were assessed for their ability to
transport glucose by the rapid filtration technique as
described previously [35]. Briefly, 50 µl of BBM vesicles
corresponding to 100 µg of protein were incubated with
150 µl of uptake buffer {150 mM sodium isothiocyanate,
50 µM d-glucose, 0.8 µCi [14C]d-glucose and 10 mM
Hepes (pH 7.5)} for various time periods (10, 20, 30, 60,
120 and 300 s). At the end of the incubation, the mixture
was diluted with 2 ml of ice-cold stop buffer [150 mM
NaCl, 10 mM Hepes and 0.2 mM phloridzin (pH 7.5)]
and immediately filtered under constant vacuum. The
filter was washed three times with 5 ml of stop buffer and
transferred to counting vials. The radioactivity retained
in the filter was counted using on LKBRack-Beta scintil-
lation counter.
Statistical analysis
Data were analysed using ANOVA, with Bonferroni
correction for multiple Student’s t test as a post hoc
test, to look for differences in the means of the various
experimental groups. A P value < 0.05 was taken to
indicate significance. Data analysis was carried out
using Statistical Package for the Social Scientist (SPSS),
version 11.
RESULTS
Effects on enterocytes
Viability of and MTT reduction by the enterocytes
were significantly decreased in indomethacin-treated cells
compared with control cells (Figures 1A and 1B). Prior
treatment with glutamine or glutamic acid restored these
parameters to near control values. Such reversal of the
effects of the drug was not seen with either glycine or
alanine pretreatment.
Measurement of activity of enzymes in the mucosal
homogenate showed that there was a significant increase
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Figure 1 Viability of (A) and MTT reduction by (B) total
enterocytes and XO (C), XDH (D) and MPO (E) activities in
mucosal homogenates isolated from control rats and rats
treated with indomethacin in the absence or presence of
the different pretreatments
Each value represents means+− S.D. (n = 6 rats). (A–E) Overall P value
for between-group comparison was < 0.001. ∗P < 0.001 compared with
control; #P < 0.001 compared with indomethacin (indo); $P < 0.001 compared
individually with indo+ glutamine and indo+ glutamic acid. (A–D) @P = 1
compared with indo. (E) @P = 0.03 and P = 0.003 when indo compared with
indo+ glycine and indo+ alanine respectively.
in the activity of XO (Figure 1C) accompanied by a
concomitant decrease in XDH in the drug-treated rats
(Figure 1D). The activity of MPO was also significantly
higher in the homogenates from these animals (Fig-
ure 1E). These effects were negated by pretreatment with
glutamine or glutamic acid. Administration of alanine or
glycine did not abolish the changes seen in response to
the drug.
Parameters of oxidative stress
Measurement of the free radical scavenging enzymes
revealed that the activities of catalase (Figure 2A), SOD
(Figure 2B), glutathione peroxidase (Figure 2C) and
Figure 2 Activities of (A) catalase, (B) SOD, (C) glutathione
peroxidase and (D) glutathione reductase in mucosal
homogenates from control rats and rats treated with
indomethacin in the absence or presence of the different
pretreatments
Values represent means+− S.D. (n = 6 rats). (A, B and D) Overall P value
for between-group comparison was < 0.001. (C) Overall P value for between-
group comparison was < 0.01. ∗P < 0.001 compared with control; #P < 0.001
compared with indomethacin (indo); $P < 0.001 compared individually with
indo+ glutamine and indo+ glutamic acid. (A, B and D) @P = 1 compared
with indo. (C) @P = 0.017 and P < 0.001 when indo compared with
indo+ glycine and indo+ alanine respectively.
glutathione reductase (Figure 2D) were significantly
lower in the homogenates from drug-treated rats com-
pared with those from control animals. All these changes
were abolished by pretreatment with glutamine or
glutamic acid, but not by glycine or alanine.
Assessment of indicators of oxidative stress showed
significant increases in the levels of MDA, conjugated
dienes and protein carbonyl and decreases in α-
tocopherol and thiols in rats treated with indomethacin
when compared with control animals (Table 1). All these
changes were abolished by pretreatment with glutamine
or glutamic acid. Pretreatment with glycine or alanine
ameliorated the effects of indomethacin in the case of
someof the parameters, but these effectsweremuch lower
in magnitude than those seen with glutamine or glutamic
acid (Table 1).
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Table 1 Levels of malondialdehyde, conjugated dienes, protein carbonyls, α-tocopherol and thiols in homogenates,
mitochondria and BBMs from control rats and rats treated with indomethacin in the absence or presence of the different
pretreatments
Values are means+− S.D. (n= 6 rats). Overall P values for between-group comparisons were < 0.01. ∗P< 0.001 compared with control; #P< 0.001 compared
with indomethacin (indo) alone; $P< 0.001 compared with indo+ glutamine; @P< 0.001 compared with indo+ glutamic acid; †P= 1 compared with indo;
‡P> 0.001< 0.05 compared with indo; §P> 0.051< 1 compared with indo.
Parameter Control Indo Indo+ glutamine Indo+ glutamic acid Indo+ glycine Indo+ alanine
Homogenate
MDA (nmol/mg of protein) 1.84+− 0.12 8.05+− 0.52∗ 1.80+− 0.04# 1.86+− 0.19# 6.51+− 0.3#$@ 7.52+− 0.63$@§
Conjugated dienes (nmol/mg of protein) 34.12+− 2.9 67.21+− 3.13∗ 35.12+− 1.52# 33.75+− 1.99# 63.98+− 3.17$@§ 59.83+− 3.29$@†
Protein carbonyl (nmol/mg of protein) 26.03+− 2.03 59+− 3.96∗ 27.91+− 0.96# 30.58+− 2.03# 55.57+− 2.55$@§ 57.19+− 1.41$@†
α-Tocopherol (nmol/mg of protein) 9.42+− 0.87 3.45+− 0.12∗ 10.65+− 0.91# 110.02+− 10.01# 4.15+− 0.15$@† 5.18+− 0.35$@‡
Total thiols (nmol/mg of protein) 29.59+− 3.03 15.07+− 1.08∗ 30.74+− 1.59# 32.09+− 2.28# 19.34+− 2.29$@‡ 18.38+− 2.46$@§
Mitochondria
MDA (nmol/mg of protein) 2.25+− 0.12 7.3+− 0.2∗ 3.2+− 0.41# 2.9+− 0.41# 7.99+− 0.88$@§ 8.87+− 0.78#$@
Conjugated dienes (nmol/mg of protein) 20.07+− 1.41 65.85+− 3.89∗ 21.33+− 1.27# 23.56+− 1.29# 56.9+− 3.88#$@ 57.29+− 3.17#$@
Protein carbonyl (nmol/mg of protein) 20.86+− 1.01 59.35+− 1.32∗ 21.5+− 1.93# 21.97+− 1.34# 60.99+− 3.37$@† 57.41+− 1.71$@†
α-Tocopherol (nmol/mg of protein) 10.47+− 0.9 4.75+− 0.24∗ 11.35+− 0.11# 12.35+− 0.94# 3.45+− 0.31$@§ 4.65+− 0.35$@†
Total thiols (nmol/mg of protein) 25.95+− 2.17 15.46+− 1.15∗ 30.08+− 2.17# 28.88+− 1.1# 17.2+− 1.65$@† 19.37+− 1.04$@‡
BBM
MDA (nmol/mg of protein) 1.75+− 0.106 6.54+− 0.36∗ 1.79+− 0.21# 1.77+− 0.15# 5.65+− 0.58$@‡ 6.19+− 0.72$@†
Conjugated dienes (nmol/mg of protein) 0.317+− 0.01 0.58+− 0.02∗ 0.30+− 0.02# 0.299+− 0.02# 0.517+− 0.05$@‡ 0.528+− 0.02$@‡
Protein carbonyl (nmol/mg of protein) 22.44+− 2.25 59.37+− 2.25∗ 23.07+− 2.78# 23.63+− 1.64# 53.19+− 2.95#$@ 51.83+− 1.53#$@
α-Tocopherol (nmol/mg of protein) 0.22+− 0.02 0.13+− 0.01∗ 0.23+− 0.02# 0.235+− 0.01# 0.166+− 0.01$@† 0.109+− 0.01$@†
Total thiols (nmol/mg of protein) 24.99+− 2.06 14.02+− 1.06∗ 28.27+− 1.88# 26.98+− 1.81# 15.91+− 1.37$@§ 17.41+− 1.01$@‡
Effects on mitochondria
Changes in mitochondrial indices were observed after
indomethacin treatment, including significant decreases
in respiratory control ratio (Figure 3A), MTT reduction
(Figure 3C) and calcium uptake (as evidenced by the
reduced fall in optical density of the calcium–arsenazo
complex; Figure 3D) and increased mitochondrial swell-
ing (as indicated by decreased absorbance at 540 nm; Fig-
ure 3B). These effects were negated by prior administra-
tion of glutamine or glutamic acid, but not with glycine
or alanine.
Oxidative stress was found to occur in these mito-
chondria, as shown by significantly elevated levels of
MDA, conjugated dienes and protein carbonyls with
significant decreases in levels of α-tocopherol and thiols.
Pretreatment with glutamine or glutamic acid abolished
these changes (Table 1). The administration of glycine
or alanine ameliorated the effects of indomethacin in
the case of some of the parameters, but these effects were
much lower in magnitude than those seen with glutamine
or glutamic acid (Table 1).
Effects on BBMs
In BBMs, the functional ability to transport glucose
across the membranes (Figure 4) was found to be de-
creased after indomethacin treatment. This decrease was
statistically significant at 20 s after incubating BBMswith
radiolabelled glucose, but not at the other time periods
measured. Pretreatment with glutamine and glutamic
acid, but not glycine and alanine, restored the functional
ability of BBMs to transport glucose.
Significant increases were seen in the levels of products
of peroxidationwith a decrease in levels of antioxidants in
BBMs from drug-treated animals (Table 1). Pretreatment
with glycine and alanine resulted in amelioration of some
of these effects, but protection afforded by glutamine or
glutamic acid was much greater and consistent for all
parameters measured (Table 1).
DISCUSSION
Glutamine is the most abundant amino acid in the body.
The small intestine is the principal organ of glutamine
consumption, extracting approx. 20–30% of circulating
glutamine in the post-absorptive state. In fact, it uses glu-
tamine as an oxidative fuel in preference to glucose
[36]. Uptake of glutamine by the enterocytes occurs
from the gut lumen across the BBM and from the
blood stream via capillaries that are adjacent to the base-
ment membrane. This avid uptake of glutamine by the
mucosal cells is due, in part, to the high activity of
the enzyme glutaminase, leading to the conversion
of glutamine into glutamic acid with the release of ammo-
nia [37].Glutamic acid is transaminated and then oxidized
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Figure 3 Respiratory control ratios (A), absorbance at
540 nm (B), MTT reduction (C) and changes in absorbance
due to the concentration of calcium in the medium (D) in
mitochondria isolated from total enterocytes from control
rats and rats treated with indomethacin in the absence or
presence of the various pretreatments
Values represent means+− S.D. (n = 6 rats). (A–D) Overall P value for
between-group comparison was < 0.001. ∗P < 0.001 compared with control;
#P < 0.001 compared with indomethacin (indo); $P < 0.001 compared
individually with indo+ glutamine and indo+ glutamic acid. (A, B and D)
@P = 1 compared with indo. (C) @P = 0.023 and P= 1 when indo
compared with indo+ glycine and indo+ alanine respectively.
in the tricarboxylic acid cycle, drivingmitochondrialATP
formation by oxidative phosphorylation. The ammonia
produced readily diffuses into the portal blood and is
extracted by the liver before it reaches the portal circu-
lation, thusmaking the gut especially suited tometabolize
glutamine.
Glutamine is known to contribute to the maintenance
of the structural integrity of mucosal enterocytes. Studies
have shown that utilization of glutamine by the gut
increases after endotoxaemia and other stresses and
appears to play a vital role in maintenance of the integrity
of the gut during critical illness [38]. It has also been
shown, by in vitro work using Caco-2 cells [39], that
depletion of glutamine in the cells leads to increased
Figure 4 Effects on D-glucose uptake by BBMs from control
rats and rats treated with indomethacin in the absence
and presence of the different pretreatments at various time
periods after incubation with radiolabelled glucose
Values represent means+− S.D. (n = 6 rats). Values at 20 s were compared
among the groups. Overall P value for between-group comparison was
P < 0.001. ∗P < 0.001 compared with control; #P < 0.01 compared with
indomethacin (indo); $P < 0.01 compared individually with indo+ glutamine
and indo+ glutamic acid; @P = 1 compared with indo.
bacterial translocation across epithelial cells. In fact,
experimental data show that glutamine administration
maintains gut barrier function in such situations [40]. In
a number of injury models, improved survival has been
demonstrated when enteral or intravenous feedings are
supplemented with glutamine [9,10].
The enterocytes of the small intestine originate
from thebase of the crypt andmigrate to the tip of the villi.
They have the apparently paradoxical dual functions of
facilitating absorption and at the same time maintaining
an effective barrier to the entry of noxious substances
from the intestinal lumen. At the apical surface of villus
epithelial cells of the small intestine are found BBMs.
These are in immediate contact with the contents of
the lumen and form an important barrier between the
lumen and the internal milieu of the epithelium. There
is evidence to indicate that, under certain circumstances,
the gut may lose its barrier function and allow entry of
intestinal bacteria into the mucosa and into the systemic
circulation. Such changes have been shown to occur in a
variety of conditions, including burn trauma [41], surgical
stress [42] and following ingestion of NSAIDs [43].
Ingestion of NSAIDs is known to result in increased
intestinal permeability, resulting in the entry of bacteria
and bile from the lumen into the mucosa. This aggravates
the damage caused to the enterocyte by the topical effect
of the drugs, leading to NSAID-induced enteropathy, a
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condition in which there is chronic loss of blood and
protein. One of the factors implicated in the pathogenesis
of this condition, in addition to the inhibition of COX,
is the decline in ATP levels in the cell, consequent upon
inhibition or uncoupling of oxidative phosphorylation
by NSAIDs [44]. The fall in ATP has been postulated to
lead to relaxation of the tight junctions in the intestinal
mucosa, thereby allowing noxious substances entry into
the mucosa.
Another mechanism that may operate in the patho-
genesis of NSAID-induced enteropathy is the alteration
of the composition of the BBMs of the small intestine,
a change that may lead to impaired barrier function.
Such changes have been observed in intestinal BBMs from
rats treated with indomethacin [8]. These effects have
been postulated to contribute to the increased intestinal
permeability that has been observed in response to the
oral ingestion of NSAIDs and the consequent loss of
barrier function [45]. In the present study, the admini-
stration of glutamine and glutamic acid was found to
protect against oxidative stress in the BBMs of the
intestinal mucosa. This protective effect may partly
account for the observation that glutamine has been
shown to attenuate the increase in intestinal permeability
caused by NSAIDs [12,13].
Other mechanisms may also contribute to the bene-
ficial effects of glutamine. The administration of gluta-
mine and glutamic acid to the experimental animals was
found to attenuate the oxidative stress in the intestinal
mucosa, with resultant abolition of the effects of indo-
methacin on themitochondria and the BBMvesicles. This
effect was not seen as consistently with other isonitro-
genous amino acids used, namely glycine and alanine.
Thus glutamine and glutamic acid offer greater protection
than glycine and alanine against indomethacin-induced
mucosal damage.
The protection offered by glutamine and glutamic
acid against such effects may be mediated by various
mechanisms. One of these involves glutathione (GSH),
which is an important cellular antioxidant. It is well
known that glutathione is one of the major mechanisms
involved in reducing oxidative stress in cells [46].
Glutamine and glutamic acid may serve as metabolic
precursors for glutathione [47]. It has been shown in
animal experiments that glutamine feeding preserved
or even increased the GSH content in the intestine
and liver after injury/ischaemia [48]. The importance of
GSH is emphasized further by a study that showed a
substantially disruptive effect on themucosal architecture
of pharmacological inhibition of GSH synthesis [49].
GSH is also known to be important for protection against
chemical injury by serving as a substrate for glutathione
transferase and glutathione peroxidase [50].
Another mechanism by which glutamine may exert its
beneficial effects in the intestine may be by its conversion
into citrulline [51], which then serves as a precursor
for synthesis of arginine, the substrate for NO (nitric
oxide) synthase, to formNO.NO is a potent vasodilator,
an inhibitor of leucocyte activation and also a scavenger of
free radicals produced by neutrophils [52]. The beneficial
effects of NO are borne out by the fact that NO-NSAID
derivatives have been shown to cause less damage to
the gastrointestinal mucosa than the parent NSAIDs
[53,54].
The protective effects of glutamine may also be
related to the attenuation of proinflammatory cytokines
subsequent to administration of the amino acid, thereby
reducing cytokine release, organ damage and mortality
[55]. Recently, it has been shown by in vitro studies
that Caco-2 cells supplemented with glutamine can
prevent cytokine-induced bacterial translocation. This
was thought to be due to glutamine acting as an energy
supplement, rather than through other mechanisms [39].
Such a hypothesis is borne out by studies that have
shown that, in models of cell injury, supplementation
with glutamine has been shown to raise levels of ATP
in tissue [56–58]. This is also supported by studies that
have documented the beneficial effects of glucose and
citrate against NSAID-induced gastrointestinal damage,
presumably by supplying substrates for the citric acid
cycle [59,60].
Glutamine supplementation is also known to enhance
induction of hsp70 (heat shock protein 70), expression
of antioxidative HO-1 (haem oxygenase 1) and anti-
apoptotic Bcl-2 molecules [61–63]. It has been reported
[64] to enhance survival of activated T-cells by down-
regulating CD95 and CD95L expression, and up-regu-
lating CD45RO and Bcl-2 expression. Other studies
of CD95-mediated caspase activities have shown that
supplementation of glutamine significantly decreased
caspase 3 and caspase 8 activities in activated T-cells [64].
Thus, in these studies, glutamine appears to protect the
cells against apoptosis.
NSAIDs are commonly used in clinical practice on
a long-term basis for the treatment of chronic inflam-
matory conditions. Long-term use, therefore, results in
cumulative toxic effects of these drugs. The currentmodel
of small intestinal toxicity has been developed, using
doses of 20 mg and 40 mg of indomethacin/kg of body
weight, to attempt to mimic, in an acute model, the long-
term effects of the drug. Both doses produced similar
effects, with differences only in the degree of change
(results not shown). The higher dose of indomethacinwas
used in the present study to assess the protective effect of
glutamine. The fact that it is protective against even the
higher dose shows that it is expected to be beneficial even
when used at lower concentrations of the drug.
In the present study, the amino acids used were sup-
plemented at a concentration of 2%. This concentration
was chosen as it was similar to that used to supplement
total parenteral nutrition in human studies [65]. Other
studies have also used this concentration of glutamine to
C© 2004 The Biochemical Society
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assess its potential as a protective agent in various animal
models of tissue injury [66,67].
In conclusion, the present study has shown that
oral supplementation with glutamine and glutamic acid
prior to indomethacin administration prevents drug-
induced alterations in the intestinal mucosa. Pretreatment
with other isonitrogenous amino acids, such as glycine
and alanine, was much less effective in this respect.
Glutamine and glutamic acid appear to act by preventing
indomethacin-induced oxidative changes in the intestinal
mucosa and BBMs. It is possible that they do this by
increasing the concentration of glutathione in themucosal
epithelial cells; however, other mechanisms may also
exist. More work is required to elucidate the precise
mechanism bywhich these amino acids confer protection
against NSAID-induced small intestinal damage.
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